Deals In Depth: March 2013
Executive Summary
AstraZeneca paid $240 million for rights to Moderna’s RNA therapeutics. Argon Medical acquired Angiotech’s interventional business for $362.5 million. PIPEs accounted for 31% of the $976 million in biopharma financing. FOPOs, on the other hand, dominated the $523 million in device fundraising.
You may also be interested in...
Final Quarter Of P&G CEO Taylor’s Tenure Could Become Stormy With Headwinds From Rising Costs
P&G’s health care sector’s net sales grew 18% in its latest quarter. Continued growth across its sectors is critical in the face of expected $1.8bn in headwinds from commodity and freight costs in its FY2022.
Off-Label Use Final Rule: US FDA Declines To Focus Solely On Promotional Claims
In final rule describing the types of evidence the agency will consider in determining the ‘intended use’ of a product, FDA rejects industry requests to exclude ‘circumstances surrounding distribution’ and product design or composition.
US FDA Publishes, Then Withdraws, PDUFA Rates Because Process ‘May Not Be Well Understood’
User fees for FY 2021 were set to increase nearly 11%, but could have gone even higher; a new notice will be issued but timing is unclear.